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ABSTRACT 
Variants of the CFH gene, encoding Complement factor H (CFH), show strong 
association with age-related macular degeneration (AMD), a major cause of blindness. Here 
we used murine models of AMD to examine the contribution of CFH to disease etiology. Cfh-
deletion protected the mice from the pathogenic subretinal accumulation of mononuclear 
phagocytes (MP) that characterize AMD, and showed accelerated resolution of inflammation. 
MP-persistence arose secondary to binding of CFH to CD11b, which obstructed the 
homeostatic elimination of MPs from the subretinal space mediated by thrombospsondin-1 
(TSP-1) activation of CD47. The AMD-associated CFH(H402) variant markedly increased 
this inhibitory effect on microglial cells, supporting a causal link to disease etiology.  This 
mechanism is not restricted to the eye, as similar results were observed in a model of acute 
sterile peritonitis. Pharmacological activation of CD47 accelerated resolution of both 
subretinal and peritoneal inflammation, with implications for the treatment of chronic 
inflammatory disease. 
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INTRODUCTION 
Age-related Macular Degeneration (AMD) is a heritable neuroinflammatory disorder 
characterized by deposits of lipoproteinaceous debris called large drusen (early AMD), 
choroidal neovascularisation (wet AMD, late form), and by an extending lesion of the retinal 
pigment epithelium (RPE) and photoreceptors (geographic atrophy, GA, late form) (Sarks, 
1976). Early AMD afflicts more than 150 million people worldwide and 10 million people 
suffer from late AMD (Wong et al., 2014). AMD is strongly associated with common and rare 
genetic variants of the CFH gene, encoding Complement factor H (CFH), suggesting a causal 
role for alterations in CFH expression or function in the pathogenesis of this disease (Fritsche 
et al., 2014). However, the mechanisms through which these alterations may lead to or 
contribute to AMD are not well understood.   
CFH is an abundant soluble plasma factor composed of 20 Short Consensus Repeat domains 
(SCR) with important roles in inflammation (Kopp et al., 2012), coagulation (Rayes et al., 
2014) and as an antioxidant (Weismann et al., 2011). The SCR7 domain of CFH binds to 
glycosaminoglycans (GAG) on cell surfaces where it inhibits complement activation (Kopp et 
al., 2012). This domain also allows CFH to bind to myeloid cells via the integrin CD11b (that 
forms with CD18 the Complement 3 Receptor), supporting myeloid cell adhesion and 
migration as well as the phagocytosis of microbes and cell debris (DiScipio et al., 1998; Kang 
et al., 2012; Losse et al., 2010). At inflammatory sites, CFH is strongly secreted by 
mononuclear phagocytes (MP), such as microglial cells (MC) and macrophages (Mφ) 
(Gautier et al., 2012; Luo et al., 2011; Schlaf et al., 2001), adding to the exudated plasma 
CFH and CFH produced by certain stromal cells such as the retinal pigment epithelium (RPE) 
in the eye (Anderson et al., 2010). 
A genetic variant that result in the substitution of histidine 402 for tyrosine (Y402H) in 
the SCR7 domain of CFH are associated with the highest risk of AMD (Fritsche et al., 2014), 
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as well as with other conditions such as smoking-associated lung cancer (Zhang et al., 2012) 
and increased mortality after cerebral hemorrhage (Appelboom et al., 2011).  This genetic 
variant is associated with both early and advanced forms of AMD (Fritsche et al., 2014), 
suggesting that CFH(H402) may drive disease onset.  
Early and advanced forms of AMD are associated with chronic accumulation of MPs in 
the subretinal space located between the RPE and photoreceptor outer segments (Combadiere 
et al., 2007; Gupta et al., 2003; Lad et al., 2015; Levy et al., 2015a; Sennlaub et al., 2013). 
Functional studies in animal models suggest that subretinal MP accumulation play a critical 
role in neovascularization and photoreceptor degeneration that characterize late AMD (Cruz-
Guilloty et al., 2013; Sennlaub et al., 2013; Tsutsumi et al., 2003). Similarly, non-resolving, 
low-grade inflammation and MP persistence contributes significantly to the pathogenesis of 
many chronic, age-related diseases such as metabolic diseases (obesity, atherosclerosis), 
neurodegenerative diseases and cancers (Nathan and Ding, 2010). In these settings, MP 
persistence is not considered causal, but rather is associated with considerable collateral 
damage to host cells, which fuels further inflammation (Nathan and Ding, 2010).  
Here we examined the contribution of CFH to the etiology of AMD.  We found a 
noncanonical role for CFH in the regulation of MP accumulation in chronic inflammation and 
in the resolution of acute inflammation. Our findings shed light on the mechanisms by which 
CFH(H402) drives sub-retinal inflammation, and further suggest that the role for CFH in 
resolution of inflammation may be relevant in various settings.  
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RESULTS 
CFH deficiency prevents chronic pathogenic subretinal inflammation 
Physiologically, the subretinal space is devoid of immune cells, including resident MCs 
(Combadiere et al., 2007; Levy et al., 2015a), due to the potent immunosuppressive pro-
apoptotic factors produced by the RPE that eliminate infiltrating leukocytes (Griffith et al., 
1995; Levy et al., 2015a). We have previously shown that high levels of Apolipoprotein E, as 
observed in subretinal MPs of AMD patients, Cx3cr1-deficient mice and humanized 
transgenic mice expressing the AMD-risk APOE2 isoform (TRE2-mice), induce chronic, age-
related and pathogenic subretinal MP accumulation (Levy et al., 2015a; Levy et al., 2015b; 
Sennlaub et al., 2013). Indeed, Cx3cr1GFP/GFP and TRE2 mice model the age-dependent 
subretinal MP accumulation and associated photoreceptor degeneration observed in human 
AMD (Combadiere et al., 2007; Levy et al., 2015b; Sennlaub et al., 2013). We therefore 
sought to determine whether Cfh deficiency would alter disease onset and progression in 
Cx3cr1GFP/GFP and TRE2 mice. Quantification of subretinal IBA-1+ MPs on retinal and 
RPE/choroidal flatmounts of 2-3 month and 12 month old animals showed that the age-related 
increase in subretinal MPs observed in both models was nearly completely blunted in the 
absence of CFH (Fig. 1A and 1B). Micrographs revealed that Cx3cr1GFP/GFP Cfh-/- mice were 
protected against the thinning of the outer nuclear layer, which hosts photoreceptor nuclei, 
usually observed in Cx3cr1GFP/GFP mice (Sennlaub et al., 2013) (Fig. 1C). Photoreceptor 
nuclei row counts (Fig. 1D) and calculation of the area under the curve showed Cfh deficiency 
protected against the photoreceptor cell loss observed in Cx3cr1GFP/GFP mice (Fig. 1E) and 
TRE2-mice (Levy et al., 2015b) (Fig. 1F), while no difference was observed in Cfh-/- 
compared to control-mice. Similarly, Cfh deficiency completely protected against cone loss 
observed on peanut agglutinin / cone arrestin stained retinal flatmounts from 12m-old 
Cx3cr1GFP/GFP mice and TRE2-mice (Fig. 1G-J). CFH did not alter the secretion of key 
pathogenic cytokines by MPs in vitro (Fig. S1), confirming that the numerical decrease of 
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MPs rather than an altered ability to produce inflammatory mediators protected Cfh deficient 
animals against the degeneration. Thus, we showed that CFH was required for the chronic, 
age-related subretinal MP accumulation and associated photoreceptor degeneration observed 
in both mouse models of AMD. A similar age- and CFH-dependent increase in MPs was also 
described in the choroid of Cfh+/- compared to Cfh-/- mice (Toomey et al., 2015). In humans, 
ocular CFH immunoreactivity is invariably stronger in AMD donor tissues (Hageman et al., 
2005; Johnson et al., 2006; Weismann et al., 2011) and CFH autoantibodies are protective in 
AMD (Dhillon et al., 2010). Together with these observations, our results strongly suggest 
CFH critically controls subretinal MP accumulation in AMD.  
CFH inhibits the resolution of acute subretinal inflammation 
Next, to better understand how CFH controls subretinal inflammation, we evaluated its 
impact on acute light-induced stress. The intensity of the light-challenge model used herein 
was calibrated to induce substantial subretinal MP infiltration in AMD-prone Cx3cr1GFP/GFP 
and TRE2 mice but not in controls (Levy et al., 2015b; Sennlaub et al., 2013 ). Quantification 
of subretinal IBA-1+ MPs revealed similar early subretinal MP accumulation in TRE2 Cfh-/- 
(Fig. 2A) and Cx3cr1GFP/GFP Cfh-/- mice (Fig. 2B) and their respective controls at the end of 
the four-day light-challenge. However, after an additional 10 days under normal light 
conditions to allow for MP clearance and inflammation resolution (Hu et al., 2015), subretinal 
MPs were eliminated significantly faster in TRE2 Cfh-/- and Cx3cr1GFP/GFP Cfh-/- mice 
compared to controls (Fig. 2A and B). Thus, our data suggest that CFH controlled MP 
persistence at the inflammatory site rather than their initial accumulation. 
Similar to Cfh-/- mice (Pickering et al., 2002), Cx3cr1GFP/GFP Cfh-/- and TRE2 Cfh-/- mice 
have low circulating levels of complement factor C3 (Fig. S2), likely due to un-inhibited 
plasma complement activation and exhaustion. To test whether the systemic lack of C3 would 
accelerate the elimination of subretinal MPs as observed in Cx3cr1GFP/GFP Cfh-/- mice, we 
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replaced hepatic CFH using hydrodynamic injection of a plasmid encoding Cfh under the 
albumin promoter. Liver Cfh complementation restored circulating C3 concentrations in 
Cx3cr1GFP/GFP Cfh-/- mice to 40-60% of the Cx3cr1GFP/GFP levels over the 14 days of the 
experimental protocol (Fig. 2C). However, the significant increase in circulating C3 levels did 
not affect the number of subretinal MPs in Cx3cr1GFP/GFP Cfh-/- mice at day 14 (Fig. 2D). 
The comparable subretinal MP counts at the beginning of acute inflammation (day 4) 
(Fig. 2A and B) and the lack of influence of circulating C3 levels during the resolution phase 
(Fig. 2D) suggested that systemic C3 was not involved in MP recruitment or their elimination. 
We next assessed relative Cfh mRNA levels in retinal and RPE/choroid tissue homogenates, 
bone marrow (BM-Mos) and circulating (Mos) monocytes as well as MCs isolated from the 
brain and retina. Our data showed that RPE/choroid and MCs expressed the highest levels of 
Cfh mRNA in WT and Cx3cr1GFP/GFP mice (Fig. 2E), in accordance with CFH protein 
localization around subretinal MPs in vivo (Fig. S2). To evaluate whether MCs- or RPE-
derived CFH would impact subretinal MP elimination, we adoptively transferred CFSE-
labeled MCs from different mouse strains into the subretinal space of either WT or Cfh-/- 
mice. The surviving CFSE+ MCs were then enumerated 24h after injection. We previously 
showed that subretinally injected WT Mos, MCs or Mϕs quickly undergo apoptosis and are 
eliminated (Levy et al., 2015a), and that such clearance is significantly delayed when MPs 
lack CX3CR1 (Levy et al., 2015a). We found Cx3cr1GFP/GFP MCs lacking Cfh were 
eliminated faster than controls (Fig. 2F). This difference could be reversed by human CFH 
(Fig. 2F). Experiments using BM-Mos revealed comparable results (Fig. S3). Interestingly, 
recipient derived-CFH only had a very minor impact on MCs elimination (Fig. 2F), 
suggesting MP-derived CFH is more important. Similarly, TRE2 Cfh-/- MCs injected in WT 
recipients were eliminated faster than controls, and adding CFH protein again reversed the 
effect (Fig. 2G). 
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In summary, our data showed that CFH did not influence initial MP recruitment but 
inhibited MP elimination during inflammation resolution. They also demonstrated that RPE- 
and liver-derived CFH had little influence on this phenotype. Indeed, MP-derived CFH was 
sufficient to inhibit MP clearance. Similar to our experiments, the observation that recipient, 
but not liver Cfh genotype, confers the AMD-risk in liver transplant patients (Khandhadia et 
al., 2013) suggests that plasma CFH is not involved in AMD pathogenesis and points to the 
importance of MP-derived CFH in the disease.  
CFH binding to CD11b inhibits MP elimination mediated by TSP-1 activation of CD47 
CFH can act as a cofactor of complement factor I (CFI) to cleave C3b into iC3b, which 
reduces C3 convertase formation, formed by C3b and activated complement factor B (CFB) 
and opsonizes (iC3b) apoptotic bodies (Martin and Blom, 2016). However, we did not detect 
C3 or activated C3 fragments in subretinal MPs of Cx3cr1GFP/GFP or Cx3cr1GFP/GFP Cfh-/- mice 
(Fig. S3) and BM-Mos and MCs only expressed low and very low levels of C3 mRNA and no 
detectable levels of Cfi mRNA in both cell types (Fig. S4). Together, these observation made 
a significant implication of locally produced C3, C3b, or iC3b in CFH-mediated inhibition of 
MP elimination unlikely. 
CFH also binds directly to the integrin CD11b (DiScipio et al., 1998; Kang et al., 2012; 
Losse et al., 2010) that was strongly expressed by MPs with no detectable differences in our 
mouse strains (Fig. S5). Flow cytometry analysis showed fluorescently labeled CFH bound 
dose-dependently to MCs (Fig. 3A) and BM-Mos isolated from Cx3cr1GFP/GFP Cfh-/- mice 
(Fig. 3B). Pre-incubation with an anti-CD11b antibody inhibited CFH binding (Fig. 3B), as 
previously demonstrated for neutrophils (DiScipio et al., 1998). As shown above (Fig. 2F), 
adding CFH to Cx3cr1GFP/GFP Cfh-/- MCs transferred subretinally in WT recipients delayed 
their elimination. This effect was no longer observed when transferred MPs were treated with 
the anti-CD11b antibody (Fig. 3C). The antibody also significantly accelerated the 
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elimination of CFH-competent Cx3cr1GFP/GFP MCs. By contrast, an anti-C3b/iC3b/C3c 
antibody that inhibits complement-induced hemolysis (clone 3/26 (Mastellos et al., 2004), had 
no effect (Fig. 3C). These results revealed that CFH binding to the CD11b integrin was 
necessary to inhibit MC elimination and suggested a C3-independent, non-canonical role of 
CFH in this mechanism. 
CD11b co-localizes with the integrin-associated protein (IAP, CD47) in lipid-rafts 
(Pfeiffer et al., 2001), a thrombospsondin 1 (THBS1, TSP-1) receptor known to potentiate 
FasL-induced endothelial cell and T cell death (Manna et al., 2005; Quesada et al., 2005). We 
therefore investigated whether CFH binding to CD11b could limit CD47 activation and 
impair MP elimination in Cx3cr1GFP/GFP and TRE2 mice. First, we found the expression level 
of TSP-1 and CD47 as well as the plasma TSP-1 levels were similar in our different mouse 
strains (Fig. S5). Next, proximity ligation assay revealed numerous complexes formed by 
CD11b and CD47 on Cx3cr1GFP/GFP Cfh-/- MCs (Fig. 3D). We next analyzed the role of CD47 
in subretinal MC clearance in adoptive transfer experiments. Subretinally injected CFSE-
labeled MCs from WT, Thbs1-/- or Cd47-/- donors into WT recipients revealed MCs lacking 
Thbs1 or Cd47 had slower elimination rates than WT MCs (Fig. 3E). Co-injected recombinant 
TSP-1 accelerated the elimination of WT MCs, reversed the phenotype of Thbs1-deficient 
MCs but had no effect on MCs lacking Cd47 (Fig. 3E), suggesting the interaction of TSP1 
with CD47 mediated MC elimination. Moreover, analysis of Thbs1-/- and Cd47-/- mice 
revealed a significant age-related (Fig. 3F) and light-induced (Fig. 3G) increase in subretinal 
MPs in these strains as compared to controls, but not in mice lacking Cd36, an alternative 
TSP-1 receptor. Overall, our results pointed to TSP-1 activation of CD47 as central in the 
maintenance of subretinal immunosuppression, and likely explained the previously reported 
increased and prolonged subretinal inflammation observed in Thbs1-/- mice (Chen et al., 2012; 
Ng et al., 2009; Wang et al., 2012). Interestingly, binding of TSP-1 to CD36 that mediates 
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endothelial cell apoptosis and is necessary for latent TGF-β activation (Febbraio et al., 2001) 
had no significant influence on subretinal MP accumulation, as observed here in Cd36-/- mice.  
Taking into account the opposing effects of TSP1 and CFH, we next evaluated their 
interaction in MP elimination. Using our adoptive transfer assay, we found a TSP-1 blocking 
antibody reversed the accelerated elimination of Cx3cr1GFP/GFP Cfh-/- MCs compared to 
controls (Fig. 3H). Furthermore, the faster elimination rate observed after supplementation of 
recombinant TSP-1 to Cx3cr1GFP/GFP Cfh-/- MCs was completely lost when purified CFH was 
concomitantly added (Fig. 3I). 
Next, we used the laser-injury model to test whether CFH binding to CD11b or CD47 
activation can accelerate inflammation resolution in CFH-competent Cx3cr1GFP/GFP mice. 
Using this model, we take advantage of the fact that laser burn induces a thinning of the retina 
above the impact, facilitating diffusion of intravitreally-injected molecules to the subretinal 
space. Our results showed that TSP-1 (Fig. 3J), CD47-activating peptide PKHB1 (a derivate 
of the 4N1K CD47-agonist peptide with improved pharmacological properties (Denefle et al., 
2016), Fig. 3K), or the anti-CD11b antibody (that blocks CFH binding to CD11b, Fig. 3L), 
injected at the height of laser-induced subretinal inflammation (d4 and d7), all significantly 
accelerated subretinal MP elimination as compared to their controls. 
Taken together, our data showed that CFH binding to the integrin CD11b inhibited 
subretinal MC elimination. We demonstrated that CD47 co-localized with CD11b on MPs 
and mediated the physiological role of TSP-1 in subretinal MP elimination. The observation 
that TSP-1 blockade reversed the effect of CFH deficiency and that recombinant CFH 
blocked the effect of TSP-1 on subretinal MP elimination strongly suggested that CFH 
binding to CD11b interfered with TSP-1 activation of CD47. We showed that TSP-1 and 
more specifically CD47 activation efficiently accelerated MP elimination similar to Cfh-
deficiency.  
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CFH inhibits the resolution of acute sterile peritonitis 
Non-resolving inflammation contributes significantly to the pathogenesis of many 
chronic, age-related diseases (Nathan and Ding, 2010). To test whether CFH influences 
inflammation resolution in other pathological contexts, we used a model of acute 
thioglycollate-induced peritonitis, characterized by an early accumulation of neutrophils, 
followed by recruited monocyte-derived inflammatory macrophages (recMφ), both 
experiencing an apoptosis-driven elimination at different kinetics (Gautier et al., 2013). 
Analysis of the ImmGen dataset (Gautier et al., 2012) (GenBank no. GSE37448) showed Cfh 
mRNA levels in thioglycollate-elicited peritoneal recMφ was approximately doubled 
compared to circulating blood Ly-6C+ Mo, from which they derive (Fig. 4A). Thus, recMφs 
likely participate to local CFH in peritonitis, in addition to extravasated plasma CFH. 
Quantification of recruited CD115+ F4/80+ ICAM2lo recMφs in Cfh-/- mice and controls (Fig. 
4B), revealed a robust and similar early accumulation 1 day after peritonitis induction (Fig. 
4C). At day 3 however, while the numbers of recMφs continued to rise in WT mice, they had 
receded by 50% in Cfh-/- mice (Fig. 4C). This observation was similar to the accelerated 
elimination of subretinal MPs observed in light-challenged TRE2 Cfh-/- and Cx3cr1GFP/GFP 
Cfh-/- mice (Fig. 2A and B). Human recombinant CFH injected into the peritoneal cavity of 
Cfh-/- mice at day 1 significantly inhibited the enhanced clearance of recMφs observed in this 
strain at day 2 as compared to heat-denatured CFH (Fig. 4D), akin to the effect we observed 
in subretinally injected Cx3cr1GFP/GFP Cfh-/- MCs (Fig. 2F). In addition, similar to our results 
in MCs (Fig. 3D), a proximity ligation assay revealed numerous and specific complexes 
CD11b and CD47 in WT recMφ retrieved at day 1 (Fig. 4E). Finally, a single intra-peritoneal 
injection of recombinant TSP-1 or the CD47-specific activating peptide PKHB1 at day 1 
significantly accelerated the elimination of recMφs as observed at day 2 (Fig. 4F). 
In summary, our results showed that CFH inhibited recMφ elimination in sterile 
peritonitis confirming findings for infiltrating MPs in the subretinal space. The observation 
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that complexes of CD11b and CD47 were present on peritoneal recMφ and that CD47 
activation accelerated recMφ elimination during peritonitis strongly suggested that CFH 
inhibited CD47-dependent inflammation resolution similarly in both the eye and the 
peritoneum. 
The CFH(H402) variant inhibits subretinal MC elimination more potently than the 
common CFH(Y402) 
The substitution of histidine 402 for tyrosine (Y402H) in CFH sequence accounts for a major 
part of the genetic risk of AMD. To test whether the Y402H polymorphism influenced the 
elimination of distinct MPs differently, we transferred CFSE-labeled Cx3cr1GFP/GFP Cfh-/- 
MCs or BM-Mos to the subretinal space together with purified CFH(Y402) or the disease 
associated CFH(H402) to WT mice. CFSE+ cell counts after 24h revealed that both isoforms 
inhibited clearance of BM-Mos (Fig. 5A) and MCs (Fig. 5B) compared to cells injected 
without CFH. However, while CFH(Y402) and CFH(H402) had similar effects on BM-Mo 
elimination (Fig. 5A), CFH(H402) limited MC clearance by 37% compared to CFH(Y402) 
(Fig. 5B). In addition, recombinant CFH(Y402)  reversed the accelerated elimination rate 
observed when subretinally injected Cx3cr1GFP/GFP Cfh-/- MCs were treated with recombinant 
TSP-1, and recombinant CFH(H402) was 50% more potent at inhibiting this phenomenon 
(Fig. 5C). 
 Taken together our results showed that CFH(H402)  was significantly more potent to 
inhibit the subretinal elimination of certain MPs, such as MCs. The CFH(H402) variant might 
thereby spur non-resolving inflammation under the retina, and thus explain its association 
with early and late AMD (Fritsche et al., 2014) where subretinal MPs accumulate (Lad et al., 
2015; Levy et al., 2015a; Sennlaub et al., 2013). 
DISCUSSION 
We report the previously unknown ability of CFH to favor subretinal MP accumulation in 
mice developing chronic, non-resolving, age-related inflammation in the eye. We extended 
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this finding to inflammation resolution in general by using models of acute inflammation in 
the peritoneum and the eye. Our work supports the long-standing association between CFH 
variant and AMD, and we uncovered the mechanisms by which CFH impacts MP infiltration, 
independently from its action in the complement cascade. 
The subretinal space is prone to MP infiltration due to light-induced oxidative stress and 
high metabolic activity (Combadiere et al., 2007; Ng and Streilein, 2001), and this is 
physiologically counterbalanced by the expression of immune-suppressive factors by the RPE 
(Griffith et al., 1995; Levy et al., 2015a). We showed that CFH favored MP accumulation by 
inhibiting their elimination mediated by TSP-1 activation of CD47. Remarkably, Thbs1-/- and 
Cd47-/- mice developed age-related subretinal inflammation under normal living conditions. 
This can possibly be explained by the sensitizing role of TSP-1 on FasL-induced cell death 
(Manna et al., 2005; Quesada et al., 2005) as FasL expression by the RPE is necessary to 
prevent subretinal MP accumulation (Griffith et al., 1995; Levy et al., 2015a). 
CFH was expressed at high levels in MCs and Mo-derived Mφs in peritonitis and we 
confirmed a step-wise binding interaction between CFH and CD11b (Gautier et al., 2012; Luo 
et al., 2011; Schlaf et al., 2001) and CD11b and CD47 (Pfeiffer et al., 2001) on MPs. The 
ligation of the sizeable CFH (1231 amino acids) to CD11b might thereby sterically hinder the 
ligation of the trimeric TSP-1 (3x1106 amino acids) to CD47, and increase MP lifespan. 
Although the exact mechanism remains to be elucidated, our data shows that complement 
activation or CFH-dependent production of iC3b, an alternative ligand of CD11b, did not play 
a detectable role in the process: C3b/iC3b/C3c fragments were not found in the subretinal 
space and CFI (necessary to produce iC3b) was not significantly transcribed in MPs. Lastly, a 
specific antibody that inhibits the alternative cascade (Mastellos et al., 2004) did not 
accelerate MP elimination. 
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In addition, we found that the AMD-associated CFH(H402) variant had an increased 
capacity to inhibit the elimination of certain MP populations, such as MCs, strengthening the 
causal link to AMD etiology. Although CFH(H402) affinity is decreased to certain GAG 
species, it is higher in particular to GAG sulfates (Clark et al., 2006). GAG sulfate profiles 
differ greatly between MPs and different microenvironments. For example, keratan sulfate 
proteoglycans (KPSG) are strongly present on ramified brain MCs but not on blood Mos 
(Wilms et al., 1999). The differential expression of GAG sulfates, such as KPSG, on MCs 
might explain why CFH(H402) differentially influenced MC but not BM-Mos elimination. 
Subretinal MPs originating from infiltrating Mo and MCs (Sennlaub et al., 2013) invariably 
express KPSG strongly (Combadiere et al., 2007; Ng and Streilein, 2001; Ng et al., 2009). 
This is also the case in spinal cord injury, but not in autoimmune neuritis (Jones and 
Tuszynski, 2002; Matsui et al., 2013). CFH(H402) might therefore have a particularly strong 
influence on subretinal inflammation observed in AMD but not necessarily in other chronic 
inflammatory diseases. In human evolution, the limited elimination of MPs and the increased 
inflammatory reaction associated with CFH(H402) might have increased survival to certain 
infectious diseases, leading to its high frequency as observed today in certain populations. In 
AMD, CFH(H402) might be pathogenic as it fuels subretinal inflammation and leads to 
chronic inflammation, which add to its decreased capacity to inhibit oxidative stress 
(Weismann et al., 2011) and to bind to Bruchs membrane (Clark et al., 2010) that protects the 
RPE against uncontrolled complement activation (Coffey et al., 2007; Toomey et al., 2015). 
Current anti-inflammatory therapies, such as steroids, non-steroidal anti-inflammatroy 
drugs (NSAID), or immunosuppressive drugs (Ciclosporin) can have paradoxical effects on 
macrophage function. They increase proinflammatory mediators (high-dose steroids) (Lim et 
al., 2007), upregulate toll-like receptors on macrophages (Ciclosporin) (Tedesco and 
Haragsim, 2012) and prolong macrophage infiltration (NSAID) (Gilroy et al., 1999), which 
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might explain their lack of therapeutic effect in AMD. Our findings introduce a new strategy 
to directly induce the elimination of pathogenic macrophage accumulation in AMD, and 
possibly other conditions, by pharmacological activation of CD47. 
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Experimental Procedures: 
Mice 
Cfh-/-, TRE2 and TRE3 mice were generous gifts from Mathew Pickering and Patrick 
Sullivan. Cx3cr1GFP/GFP, Thbs1-/-, Cd47-/-, and Cd36-/- mice were obtained for The Jackson 
laboratories, Cx3cr1GFP/GFP Cfh-/- and TRE2 Cfh-/- mouse strains were generated, all mice were 
either negative or backcrossed to eliminate the Pde6brd1, Gnat2cpfl3, and Crb1rd8 mutations. 
The mice were kept to the indicated ages under specific pathogen-free condition in a 12h/12h 
light/dark (100 lux) cycle with no additional cover in the cage, and with water and normal 
chow diet available ad libitum. 
Aging, light challenge- and laser-injury model 
Mice were exposed to green LED light (4500 Lux) for 4 days and subsequently kept in 
cyclic conditions (Sennlaub et al., 2013). Laser-coagulations were performed on male mice 
(Vitra Laser, 532nm, 450 mW, 50ms, and 250μm), intravitreally injected (day 4 and 7) with 
2μl of PBS, recombinant human TSP-1 (10µg/ml), the 4NGG control peptide or the PKHB1 
CD47-activating peptide (200µM), anti-CD11b antibody (50µg/ml), isotype control rat IgG2 
(50µg/ml), and sacrificed at day 10. All experimental procedures were approved by the local 
animal care ethics committee C2EA-05 - Charles Darwin. 
Histology and Immunohistochemistry 
After fixation the eyes were cryo-sectioned (10μm), and stained with anti-C3-, anti-
C3b/iC3b/C3c-, and anti-CFH-antibodies and appropriate secondary antibodies, or dissected 
for flatmount preparations. The retinas and choroids were incubated with Peanut agglutinin, 
anti-IBA-1, anti-cone arrestin, or anti-CD102 antibodies as indicated, followed by appropriate 
conjugated secondary antibodies. IBA-1+ cells were counted on whole RPE/choroidal 
flatmounts and on the outer segment side of the retina. PA+ cone arrestin+ cells were counted 
on oriented retinal flatmounts. For histology the eyes were fixed, embedded in Historesin, cut 
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(5µm sagittal sections) and stained with toluidin blue. Rows of nuclei in the outer nuclear 
layer (ONL) were counted at different distances from the optic nerve.  
Hydrodynamic injection 
Empty pLIVE plasmid and coding for murine CFH was intravenously  injected to mice 
as previously described (Rayes et al., 2010). Four days later, mice were exposed to the light 
challenge model and their blood was sampled to quantify plasma C3 concentration by ELISA.  
Plasma and mononuclear phagocyte preparations, analysis, and culture 
Plasma C3 and TSP-1 levels were measured by ELISA. Mos from the blood and bone 
marrow were isolated by negative selection. MCs from brain and retina were isolated with 
anti-CD11b microbeads. No (CFH-containing) serum was used in any step of the purification. 
Cells were used for adoptive transfer experiments, analyzed by RT-qPCR or cultured for 24h 
in serum free DMEM, in presence of recombinant human APOE3, and finally their 
supernatants were analyzed by cytokine multiplex array. 
Subretinal adoptive microglial cell transfer and clearance  
Brain MCs from male mice were sorted, labeled with CFSE, and injected in the 
subretinal space (verified by fundoscopy) of WT or Cfh-/- male mice in 4µl of PBS, purified 
human or recombinant CFH, CFH(Y402), and CFH(H402) (500μg/ml), recombinant human 
TSP-1 (10µg/ml), and following antibodies (10µg/ml); anti-CD11b, anti-C3b/iC3b/C3c, 
isotype control rat IgG2, anti-TSP-1, and isotype control mouse IgM. After 24 hours, CFSE+ 
cells in the subretinal space were quantified on whole RPE/choroidal and retinal flatmounts. 
Thioglycollate induced peritonitis and flow cytometry 
Peritonitis was induced by intraperitoneal injections of 0.5 ml of 3% (wt/vol) thioglycollate 
broth in male mice. At 24 hours mice were injected with 100μl of PBS containing native or 
heat inactivated purified commercial human CFH (500μg/ml), recombinant human TSP-1 
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(50µg/m), the CD47-activating peptide PKHB1 or the 4NGG control peptide (500µM), and 
exudate cells were analyzed using a BD Fortessa flow cytometer. 
CFH binding assay by flow cytometry 
MCs from Cx3cr1GFP/GFP Cfh-/- were stained 30 minutes with Cy5.5-conjugated human 
CFH at 37°C and washed before acquisition on a BD Fortessa flow cytometer. Bone marrow 
monocytes were preincubated with control IgG or anti-CD11b antibody (clone 5C6) at 
10µg/ml, and incubated with hCFH-Cy3.  
CD11b-CD47 proximity ligation assay  
Duolink® PLA assay was performed following the manufacturer’s instructions with 
rabbit anti-CD11b and goat anti-CD47 on day 1 thioglycollate elicited peritoneal Mφs, and 
brain MCs.  
Statistical analysis 
Graph Pad 7 (GraphPad Software) was used for data analysis and graphic 
representation. All values are reported as mean ± SEM. Statistical analysis and variance 
analysis was performed by one-way ANOVA followed by Bonferroni post-test (for multiple 
comparison) or Mann-Whitney U-test (2-group comparison) among means depending on the 
experimental design. The n and P-values are indicated in the figure legends.  
Please see supplemental information for more details. 
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Figure Legends 
 
Figure 1. CFH deficiency prevents chronic pathogenic subretinal inflammation 
A and B: (A) Representative images of 12 month-old IBA-1 (green) stained RPE 
flatmounts of Cx3cr1GFP/GFP and Cx3cr1GFP/GFP Cfh-/- mice and (A and B) quantification of 
subretinal IBA-1+ MPs in 2-3 months and 12 months old mice of the indicated strains (A: 
one-way Anova/Bonferroni test *p˂0,0001 versus all other groups, Mann Whitney $p<0.0001 
versus Cx3cr1GFP/GFP at 12 months of age; B: one-way Anova/Bonferroni test *p˂0,0001 
versus all other groups, Mann Whitney $p=0.0003 versus TRE2 at 12 months of age). 
C-F: (C) Micrographs, taken 1000 m from the optic nerve, of 12 month-old 
Cx3cr1GFP/GFP and Cx3cr1GFP/GFP Cfh-/- mice. (D) Photoreceptor nuclei rows at increasing 
distances (-3000m: inferior pole, +3000m: superior pole) from the optic nerve (0m) in 12 
month-old mice. (E and F) Quantification of the area under the curve of photoreceptor nuclei 
row counts of 12 month-old mice of the indicated transgenic mouse strains (E: one-way 
Anova/Bonferroni test: *p˂0,0001 versus all other groups; Mann Whitney $p=0,0024 versus 
Cx3cr1GFP/GFP  mice; F: one-way Anova/Bonferroni test: *p˂0,001 versus all other groups; 
Mann Whitney $p=0,0158 versus TRE2 mice). 
G-J: (G) Micrographs, taken in the superior periphery of peanut agglutinin (staining 
cone segments, red), cone arrestin (white), IBA-1 (green) triple stained 12 month-old 
Cx3cr1GFP/GFP and Cx3cr1GFP/GFP Cfh-/- mice. (H) Cone density quantifications on retinal 
flatmounts in peripheral and central, inferior and superior retina (-3000m: inferior pole, 
+3000m: superior pole, optic nerve: 0m) and their average (I and J) in 12 month-old mice 
of the indicated transgenic mouse strains (I: one-way Anova/Bonferroni test: *p˂0,0001 
versus all other groups; Mann Whitney $p=0,0024 versus Cx3cr1GFP/GFP  mice; J: one-way 
Anova/Bonferroni test: *p˂0,0001 versus all other groups; Mann Whitney $p=0,0158 versus 
TRE2 mice). 
TRE2 and TRE3: Targeted replacement mice expressing human APOE 2 and 3 isoforms 
ONL: outer nuclear layer; Scale bar A and C = 50m. 
n= number of replicates indicated in the graphs; replicates represent quantifications of 
eyes from different mice of at least three different cages. 
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Figure 2. CFH inhibits the resolution of acute subretinal inflammation 
A and B: (A) Representative images of IBA-1 (green) stained RPE flatmounts of light-
challenged TRE2 and TRE2 Cfh-/- mice and (A and B) quantification of subretinal IBA-1+ 
MPs in non-illuminated (NI), 4 days-light challenged (d4), and 4 days-light challenged 
followed by 10 days of recovery (d4+10) of 2-3 months old mice of the indicated strains. (A: 
one way Anova/Bonferroni test *p˂0,0001 versus the NI groups and TRE3 mice at d4, 
$p<0.0001 versus TRE2 d4+10; MannWhitney $p=0,0004 versus TRE2 at d4+10; B: one way 
Anova/Bonferroni test *p˂0,0001 versus the NI groups and C57BL6/J mice at d4, $p<0.0001 
versus Cx3cr1GFP/GFP at d4+10; MannWhitney $p=0,0002 versus Cx3cr1GFP/GFP at d4+10). 
C: Quantification by ELISA of circulating plasma C3 in control animals and after 
hypervolemic liver transfection with a control plasmid (ctl Pl) or a plasmid encoding murine 
CFH (mCFH) in 2-3 months old Cx3cr1GFP/GFP and Cx3cr1GFP/GFP Cfh-/- mice. Measurements 
were performed before (d0), at the end (d4) and ten days after (d14) the light-challenge. (one 
way Anova/Bonferroni test at d0 *p=0,0003, d4 *p=0,0018, d4+10 *p=0,0009 compared to 
control plasmid injected mice at each time point). 
D: Quantification of subretinal IBA-1+ MPs/mm2 in light-challenge model at day 14 in 
2-3 month-old Cx3cr1GFP/GFP and Cx3cr1GFP/GFP Cfh-/- mice after hypervolemic liver 
transfection of the empty plasmid or the plasmid encoding murine CFH. (Mann Whitney = 
0,1). 
E: Quantitative RT-PCR of Cfh mRNA normalized to Rps26 mRNA expression in 
retina, choroid/RPE, circulating monocytes (cMo), bone marrow monocytes (BM-Mo), retinal 
microglia (MC Retina) and brain microglia from the indicated strains (n=replicates from 
individual mice except for retinal MCs which represent 3 preparations from 5 pooled mice 
each). 
F: Representative micrograph of CFSE+ MCs on RPE flatmounts of the indicated strains 
24h after subretinal adoptive transfer to Cfh-/- mice. Quantification of CFSE+ MCs of the 
indicated strains 24h after adoptive transfer to WT C57BL6/J or Cfh-/- mice, with or without 
purified human CFH (one way Anova/Bonferroni test *p˂0,001 versus C57BL6/J CFSE+ 
MCs in C57BL6/J recipients, $p=0,0043 versus Cx3cr1GFP/GFP CFSE+ MCs in C57BL6/J 
recipients, †p=0,0139 versus Cx3cr1GFP/GFP Cfh-/- CFSE+ MCs in C57BL6/J recipients; there 
were no significant differences between groups injected in WT C57BL6/J or Cfh-/- recipients 
for each cell genotype). 
G: Quantification of subretinal CFSE+ MCs of the indicated strains 24h after adoptive 
transfer to C57BL6/J WT mice, with or without purified human CFH (one way 
Anova/Bonferroni test *p=0,0009 versus C57BL6/J CFSE+ MCs, $p=0,0012 versus TRE2 
CFSE+ MCs, †p=0,0085 versus TRE2 Cfh-/- CFSE+ MCs). 
n=number of replicates presented in the graphs; for A, B and D n=replicates represent 
quantifications of eyes from different mice of at least three different cages;  for F and G 
n=replicates from individual mice from three experiments with three different cell 
preparations. TRE2 and TRE3: Targeted replacement mice expressing human APOE 2 and 3 
isoforms; post-transf.: post-transfection; light-chall: light-challenge; ctlPL: control plasmid; 
mCFH: murine CFH plasmid; Scale bar A and F = 50m. 
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Figure 3. CFH binding to CD11b inhibits MP elimination mediated by TSP-1 activation 
of CD47 
A and B: Representative cytometry plots of (A) sorted brain Cx3cr1GFP/GFP Cfh-/- 
Microglial Cells (gated on GFPhigh) incubated with increasing dose of hCFH::Cy5.5 
(15,625μ/ml to 500μg/ml), and (B) sorted Cx3cr1GFP/GFP Cfh-/- bone marrow monocytes pre-
incubated with an isotype IgG or anti-CD11b IgG (5C6 clone) before hCFH::Cy3 or PBS 
incubation. Bone marrow monocytes were gated as GFP+ CD115+ Ly-6G- cells (the 
experiments were repeated three times with similar results). 
C: Representative micrograph of subretinal Cx3cr1GFP/GFP Cfh-/- CFSE+ MCs on RPE 
flatmounts 24h after subretinal adoptive transfer injection together with CFH and control IgG 
or anti-CD11b IgG (clone 5C6) and Cx3cr1GFP/GFP CFSE+ MCs with control IgG,  anti-
CD11b IgG (clone 5C6) or anti-C3b/iC3b/C3c IgG (clone 3/26) to WT C57BL6/J mice and 
quantification of the indicated groups (Anova/Bonferroni test †p=0.0034 versus Cx3cr1GFP/GFP 
Cfh-/- CFSE+ MCs without CFH, ‡ p=0,0036 versus Cx3cr1GFP/GFP Cfh-/- + CFH + cIgG, Mann 
Whitney *p=0,0083 versus cIgG;). 
D: Representative confocal micrographs of CD11b-CD47 complexes (red dots) detected 
by proximity ligation assay on freshly isolated brain Cx3cr1GFP/GFP Cfh-/- MCs counterstained 
with Hoechst nuclear stain (blue; negative control: omitting the primary antibodies; the 
experiment was repeated three times with similar results). 
E: Quantification of subretinal CFSE+ MCs of the indicated strains 24h after adoptive 
transfer to WT C57BL6/J mice with and without recombinant TSP-1 (n=replicates from 
individual mice from experiments with three different cell preparations; one-way 
Anova/Bonferroni test ‡p=0,0359 versus C57BL6/J CFSE+ MCs without TSP-1;  *p˂0,0001 
versus C57BL6/J CFSE+ MCs without TSP-1; $p<0.0001 versus Tsp1-/- CFSE+ MCs without 
TSP-1; †p=0,0002 versus C57BL6/J CFSE+ MCs without TSP-1). 
F and G: Representative images of 12 month-old IBA-1 (green) stained RPE flatmounts 
of C57BL6/J and Cd47-/- mice and quantification of subretinal IBA-1+ MPs of WT C57BL6/J, 
Thbds1-/-, Cd47-/- mice and Cd36-/- mice at (F) 2-3 months and 12 months and (G) after a 4 
day-light challenge, followed by 10 days of recovery (n=replicates represent quantifications 
of eyes from different mice of at least three different experiments and cages; one-way 
Anova/Bonferroni test F: *p˂0,0001 versus 2-3 months old Thbds1-/- mice and 12 months old 
C57BL6/J mice; †p ˂0,0001 versus 2-3 months old Cd47-/- mice and 12 months C57BL6/J 
mice; G: *p˂0,0001 versus C57BL6/J; †p ˂0,0001 versus C57BL6/J). 
H and I: Quantification of subretinal Cx3cr1GFP/GFP Cfh-/- CFSE+ MCs with (G) control 
IgM or anti-TSP-1 IgM (clone A4.1) 24h after adoptive transfer (Mann Whitney *p=0,0002 
IgM versus anti-TSP-1) or (H) recombinant TSP-1 (rTSP1) and rTSP1 + purified CFH (one-
way Anova/Bonferroni test $p=0,0024 versus Cx3cr1GFP/GFP Cfh-/- CFSE+ MCs without 
rTSP1; *p=0,0003 versus Cx3cr1GFP/GFP Cfh-/- CFSE+ MCs + rTSP). 
J-L: (I) Representative micrographs of RPE flatmounts of CD102 (red) and IBA-1 (green) 
immunohistochemistry and quantification of subretinal IBA-1+ MPs on the RPE counted at a 
distance of 0-500μm from CD102+ CNV 10 days after the laser-injury in 2 month-old 
Cx3cr1GFP/GFP mice injected at day 4 and day 7 with (I) PBS or rTSP1, (J) control peptide 
4NGG or CD47-activating peptide PKHB1, and (K) control IgG or anti-CD11b IgG (Mann 
Whitney I *p=0,0097; J *p<0,0001; K *p=0,0298) 
Thbs: thrombospondin 1 gene; TSP-1: thrombospondin. n=number of replicates 
indicated in the graphs, for C, E, G and H n=replicates from individual mice from 
experiments with three different cell preparations, for F, I and J n=replicates represent 
quantifications of eyes from different mice of at least three different experiments and cages. 
Scale bar: C, F and I = 50m; D left panels =20m, right panel =10m. 
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Figure 4. CFH inhibits the resolution of acute sterile peritonitis 
A: Normalized signal intensity for Cfh mRNA levels extracted from Affymetrix 
transcription analysis of bone marrow monocytes (1), Ly-6C+ circulating blood monocytes 
(2), MHC-II- and MHC-II+ monocyte-derived peritoneal macrophages at day 5 of 
thioglycollate-induced peritonitis in 3 months old WT C57BL6/J mice (3 and 4; one-way 
Anova/Bonferroni test †p=0,0036 versus blood monocytes; *p=0,0005 versus blood 
monocytes). 
B: Representative cytometry plots of WT C57BL6/J (upper panels) or Cfh-/- mice (lower 
panels) three days after thioglycollate-induced peritonitis. CD115+ F4/80+ cells represents 
macrophages, with CD115+ F4/80+ ICAM-2lo representing Mo-derived Mφ and CD115+ 
F4/80+ ICAM-2hi representing resident macrophages. 
C: Quantification of CD115+ F4/80+ ICAM-2lo Mo-derived Mφ in exudates of WT 
C57BL6/J and Cfh-/- mice at indicated time points after thioglycollate-induced peritonitis 
(one-way Anova/Bonferroni test †p=0,012 versus d0 WT C57BL6/J; *p=0,005 versus d0 Cfh-/-
; p=0,9697 between d1 groups; $p<0,0001 versus d3 WT C57BL6/J). 
D: Quantification of CD115+ F4/80+ ICAM-2lo Mo-derived Mφ in exudates of Cfh-/- 
mice at day 2 (d2) after mice were injected with native (CFH) or heat-denatured (dCFH) 
purified CFH at day 1 (d1) (MannWhitney *p=0,0087 versus dCFH). 
E: Representative confocal micrographs of CD11b-CD47 complexes (red dots) detected 
by proximity ligation assay on freshly harvested Mo-derived Mφ 1 day after thioglycollate 
injection in WT C57BL6/J and Cd47-/- mice. Hoechst was used for nuclear stain (blue; 
negative control: omitting the primary antibodies; the experiment was repeated three times 
with similar results). 
F: Quantification of CD115+ F4/80+ ICAM-2lo Mo-derived Mφ in exudates of WT 
C57BL6/J mice at day 2 after mice were injected with PBS or rTSP-1 (Mann Whitney 
$p=0,0048); or control peptide 4NGG or CD47-activating peptide PKHB1 (Mann Whitney 
$p=0,0087) at day 1. 
Mφ: macrophage; Mo: monocyte; Thio: thioglycollate; MHC: major histocompatibility 
complex; dCFH: heat-denatured CFH; negCTL: negative control. n= number of replicates 
indicated in the graphs; replicates represent quantifications of exudate cells from different 
mice of three (C) or two (E and F) different peritonitis inductions. Scale bar: E=10m. 
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Figure 5. The CFH(H402) variant inhibits subretinal MC elimination more potently 
than the CFH(Y402) form. 
A: Quantification of subretinal Cx3cr1GFP/GFP Cfh-/- CFSE+ monocytes on RPE and 
retinal flatmounts 24h after adoptive transfer to WT C57BL6/J mice with and without purified 
CFH(Y402) or CFH(H402) (Anova/Bonferroni test 
*p˂0,0001) 
B: Quantification of subretinal Cx3cr1GFP/GFP Cfh-/- CFSE+ microglial cells on RPE and 
retinal flatmounts 24h after adoptive transfer to WT C57BL6/J mice with and without purified 
CFH(Y402) or CFH(H402) (Anova/Bonferroni test 
*p=0,0025 versus without CFH; 
†p=0,0052 versus CFH(H402)). 
C: Quantification of subretinal Cx3cr1GFP/GFP Cfh-/- CFSE+ microglial cells on RPE and 
retinal flatmounts 24h after adoptive transfer to WT C57BL6/J mice without or with 
recombinant TSP-1 (rTSP1), rTSP1 + recombinant CFH(Y402) or rTSP1 + recombinant 
CFH(H402) (Anova/Bonferroni test 
$p=0,00236 versus without TSP-1; †p=0,0002 versus with 
TSP-1;‡p=0,0005 versus with TSP-1 + CFHY402). 
Mos: monocytes; MCs: microglial cells; rTSP1: recombinant TSP-1; n=number of 
replicates indicated in the graphs, replicates represent quantifications from individual mice 
from two (A) to three (B and C) experiments with three different cell preparations. 
 
 
